Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Oct
12
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
Cancer Statistics 2026: Incidence, Mortality, Survival, and Disparities in U.S. Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo